FDA & Depth Strategic growth opportunity around Quicktome Deep Brain DBS workflow leveraging 510(k) clearance to expand neuromodulation collaborations and patient-specific treatment planning with neurotechnology partners and implant manufacturers.

Global Expansion capitalize on recent international financing and Australian government support to accelerate global deployment of AI-driven brain mapping; target clinics, hospitals, and research centers in neurology, neurosurgery, and neuromodulation markets.

Commercial Momentum Leverage Series D and C funding milestones to engage enterprise buyers with scalable SaaS/AI platform deployments; emphasize ROI in prognosis, planning, and surgical outcomes to drive multi-site contracts.

Regulatory Readiness Position as a compliant partner with ISO 13485 experience and GMLP governance to win bids requiring robust quality systems, post-market surveillance, and regulatory submissions for medical device integrations.

Key Partnerships Identify opportunities with neurosurgical centers, DBS device manufacturers, and academic consortia for co-development, data sharing, and validation studies to expand Quicktome adoption and deepen connectomics-based care.